FGF19 and metabolic dysfunction-associated steatohepatitis: There is another study also demonstrating profound antisteatotic, anti-inflammatory, and antifibrotic activities of a therapy based on the administration of engineered FGF19 variant in diet-induced mouse models of non-alcoholic steatohepatitis (NASH) [39].